IN2014CN04406A - - Google Patents
Info
- Publication number
- IN2014CN04406A IN2014CN04406A IN4406CHN2014A IN2014CN04406A IN 2014CN04406 A IN2014CN04406 A IN 2014CN04406A IN 4406CHN2014 A IN4406CHN2014 A IN 4406CHN2014A IN 2014CN04406 A IN2014CN04406 A IN 2014CN04406A
- Authority
- IN
- India
- Prior art keywords
- oxadiazol
- fluoro
- phenyl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- OOUGLTULBSNHNF-UHFFFAOYSA-N 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2N=C(ON=2)C=2C(=CC=CC=2)F)=C1 OOUGLTULBSNHNF-UHFFFAOYSA-N 0.000 abstract 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 abstract 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 abstract 1
- 229920001100 Polydextrose Polymers 0.000 abstract 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000008119 colloidal silica Substances 0.000 abstract 1
- 229960000913 crospovidone Drugs 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229920001992 poloxamer 407 Polymers 0.000 abstract 1
- 229940044476 poloxamer 407 Drugs 0.000 abstract 1
- 239000001259 polydextrose Substances 0.000 abstract 1
- 235000013856 polydextrose Nutrition 0.000 abstract 1
- 229940035035 polydextrose Drugs 0.000 abstract 1
- 229940050929 polyethylene glycol 3350 Drugs 0.000 abstract 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 abstract 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 239000000375 suspending agent Substances 0.000 abstract 1
- 239000008371 vanilla flavor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78733306P | 2006-03-30 | 2006-03-30 | |
| US81308506P | 2006-06-12 | 2006-06-12 | |
| PCT/US2007/008268 WO2007117438A2 (en) | 2006-03-30 | 2007-03-29 | Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN04406A true IN2014CN04406A (https=) | 2015-09-04 |
Family
ID=38480572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN4406CHN2014 IN2014CN04406A (https=) | 2006-03-30 | 2007-03-29 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9289398B2 (https=) |
| EP (2) | EP2007365A2 (https=) |
| JP (2) | JP5367563B2 (https=) |
| CN (1) | CN101505739A (https=) |
| AU (1) | AU2007235524B2 (https=) |
| BR (1) | BRPI0710213A2 (https=) |
| CA (1) | CA2647903C (https=) |
| IL (2) | IL194454A (https=) |
| IN (1) | IN2014CN04406A (https=) |
| MX (1) | MX2008012515A (https=) |
| NO (1) | NO20084488L (https=) |
| NZ (2) | NZ571899A (https=) |
| RU (1) | RU2462246C2 (https=) |
| SG (1) | SG170819A1 (https=) |
| WO (1) | WO2007117438A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE047569T2 (hu) | 2003-04-11 | 2020-04-28 | Ptc Therapeutics Inc | 1,2,4-oxadiazol-benzoesav vegyület és nonszensz szupresszióra történõ alkalmazása |
| USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
| EP2421971B1 (en) | 2009-04-24 | 2016-07-06 | BioMarin Technologies B.V. | Oligonucleotide comprising an inosine for treating dmd |
| EP2251437B1 (en) * | 2009-05-13 | 2013-12-04 | Hannelore Breitenbach-Koller | Method for identifying compounds that control the translational activity of ribosomal proteins in differential mRNA expression |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| NZ627896A (en) | 2012-01-27 | 2016-11-25 | Biomarin Technologies B V | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
| CA2894399A1 (en) | 2012-12-06 | 2014-06-12 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| CN103074346A (zh) * | 2013-01-22 | 2013-05-01 | 山西大学 | 一种用于促通读药物筛选的有限细胞株的建立方法 |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| KR102497273B1 (ko) * | 2014-03-06 | 2023-02-07 | 피티씨 테라퓨틱스, 인크. | 1,2,4-옥사디아졸 벤조산의 약학 조성물 및 염 |
| ES2885181T3 (es) * | 2014-04-15 | 2021-12-13 | Vertex Pharma | Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística |
| JP2016155900A (ja) * | 2015-02-23 | 2016-09-01 | 株式会社フジミインコーポレーテッド | 研磨用組成物、研磨方法及び硬脆材料基板の製造方法 |
| JP2018531975A (ja) | 2015-10-30 | 2018-11-01 | ピーティーシー セラピューティクス，インコーポレーテッド | てんかんの治療方法 |
| US11135221B2 (en) | 2015-12-23 | 2021-10-05 | Moonshot Pharma Llc | Methods for inducing an immune response |
| WO2018050706A1 (en) * | 2016-09-13 | 2018-03-22 | Marco Cipolli | Method of treatment of shwachman-diamond syndrome |
| JP2020525434A (ja) | 2017-06-22 | 2020-08-27 | ムーンショット ファーマ エルエルシー | アンレキサノクス及び免疫調節剤を含む組成物で癌を治療する方法 |
| CN107916252B (zh) * | 2017-11-17 | 2021-01-22 | 首都儿科研究所 | 一株用于验证脊肌萎缩症的永生淋巴细胞株 |
| EP3952867A4 (en) * | 2019-04-10 | 2023-01-11 | PTC Therapeutics, Inc. | METHODS OF TREATMENT OF NONSENSE MUTATION MEDIATED DUCHENNE MUSCULAR DYSTROPHY IN PEDIATRIC PATIENTS |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL291628A (https=) | 1962-04-17 | |||
| US3325446A (en) | 1964-04-17 | 1967-06-13 | Allied Chem | Stabilized halogen-containing olefin polymer compositions and stabilizers therefor |
| US4022901A (en) | 1975-03-05 | 1977-05-10 | E. R. Squibb & Sons, Inc. | 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles |
| JPS51143669A (en) | 1975-06-06 | 1976-12-10 | Takeda Chem Ind Ltd | A process for preparing 1,2,4- oxadiazole derivatives |
| US4016170A (en) | 1975-07-28 | 1977-04-05 | Sandoz, Inc. | Oxadiazolyl benzamides |
| US4166732A (en) | 1977-05-12 | 1979-09-04 | Monsanto Company | Oxadiazol-5-yl-benzoates |
| US4135910A (en) | 1977-05-12 | 1979-01-23 | Monsanto Company | Oxadiazol-3-yl-benzoates as plant growth regulants |
| US4210762A (en) | 1978-08-17 | 1980-07-01 | Monsanto Company | 2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates |
| US4268299A (en) | 1978-08-17 | 1981-05-19 | Monsanto Company | Method and composition for plant growth regulation containing trifluoromethyl 1,3,4 oxadiazol benzoates |
| EP0036711B1 (en) | 1980-03-22 | 1985-12-04 | Fbc Limited | Pesticidal heterocyclic compounds, processes for preparing them, compositions containing them, and their use |
| DE3148449C1 (de) | 1981-12-08 | 1983-06-01 | Heidelberger Druckmaschinen Ag, 6900 Heidelberg | Verfahren zur Verringerung von Registerfehlern und Druckmaschine zur Durchfuehrung des Verfahrens |
| GB8802142D0 (en) | 1988-02-01 | 1988-03-02 | Air Prod & Chem | Method of freezing liquid & pasty products & freezer for carrying out said method |
| US5037052A (en) | 1989-04-21 | 1991-08-06 | Crisp Joe E | Clamp assembly system |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| US5036761A (en) | 1989-11-20 | 1991-08-06 | Wingo Patrick Y | Forced flow press dampening apparatus |
| US4984286A (en) | 1989-12-12 | 1991-01-08 | Analogic Corporation | Spatial filter system |
| US5036762A (en) | 1990-06-12 | 1991-08-06 | Sarda Jean Lucien | Apparatus for supplying offset printing presses with a cooled damping solution |
| CA2092323A1 (en) | 1990-10-01 | 1992-04-02 | George Y. Wu | Targeting viruses and cells for selective internalization by cells |
| CA2103064A1 (en) | 1991-05-14 | 1992-11-15 | George Y. Wu | Targeted delivery of genes encoding immunogenic proteins |
| DK0587738T3 (da) | 1991-06-05 | 2000-12-18 | Univ Connecticut | Destineret levering af gener, som koder for sekretionsproteiner |
| AU3434393A (en) | 1992-01-17 | 1993-08-03 | Regents Of The University Of Michigan, The | Targeted virus |
| EP0633943A4 (en) | 1992-04-03 | 1997-05-02 | Alexander T Young | GENTHERAPY USING TARGETED VIRAL VECTORS. |
| ES2157225T3 (es) | 1992-10-09 | 2001-08-16 | Advanced Tissue Sciences Inc | Celulas hepaticas de reserva. |
| EP1024198A3 (en) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
| DE4320801A1 (de) | 1993-06-23 | 1995-01-05 | Fahlberg List Pharma Gmbh | 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel |
| US5484944A (en) | 1993-10-27 | 1996-01-16 | Neurogen Corporation | Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands |
| US5942496A (en) | 1994-02-18 | 1999-08-24 | The Regent Of The University Of Michigan | Methods and compositions for multiple gene transfer into bone cells |
| US5962427A (en) | 1994-02-18 | 1999-10-05 | The Regent Of The University Of Michigan | In vivo gene transfer methods for wound healing |
| RU2164419C2 (ru) * | 1994-03-18 | 2001-03-27 | Мириад Дженетикс, Инк. | Ген mts, мутации данного гена и способы диагностики злокачественных опухолей с использованием последовательности гена mts |
| TW343965B (en) | 1994-03-30 | 1998-11-01 | Hoffmann La Roche | Novel mono- and bicyclic DNA gyrase inhibitors |
| CZ66498A3 (cs) | 1995-09-07 | 1998-07-15 | Novartis Ag | Substituované fosfinové kyseliny, způsoby jejich přípravy, farmaceutický prostředek, který je obsahuje, a jejich použití |
| DE19620041A1 (de) | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| US6034106A (en) | 1996-06-07 | 2000-03-07 | Merck & Co., Inc. | Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity |
| WO1997046556A1 (en) | 1996-06-07 | 1997-12-11 | Merck & Co., Inc. | OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
| DE19626318A1 (de) | 1996-07-01 | 1998-01-08 | Basf Ag | Farbstoffmischungen, enthaltend Polyazofarbstoffe |
| ZA98371B (en) | 1997-01-31 | 1999-07-16 | Du Pont | Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides. |
| US6180648B1 (en) | 1997-04-07 | 2001-01-30 | Biostream Therapeutics, Inc. | Analogs of cocaine |
| US6004933A (en) | 1997-04-25 | 1999-12-21 | Cortech Inc. | Cysteine protease inhibitors |
| TR200002482T2 (tr) * | 1998-02-26 | 2002-10-21 | Aventis Pharmaceuticals Inc. | 6,9-Diikameli 2-(Trans-(4-Aminosiklohekzil) Amino)Pürinler |
| AU750369B2 (en) | 1998-04-23 | 2002-07-18 | Cortech, Inc. | Cysteine protease inhibitors |
| CA2346396C (en) | 1998-10-09 | 2009-04-28 | Janssen Pharmaceutica N.V. | 4,5-dihydro-isoxazole derivatives and their pharmaceutical use |
| EP1126833A4 (en) | 1998-10-29 | 2004-09-08 | Trega Biosciences Inc | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES CONTAINING THESE DERIVATIVES |
| KR100630986B1 (ko) | 1998-12-23 | 2006-10-09 | 스미스클라인 비참 코포레이션 | 프로테아제 억제제 |
| EP1157274A1 (en) * | 1999-03-02 | 2001-11-28 | The University of Dundee | Methods of determining altered ndpk functions |
| WO2000058278A1 (fr) | 1999-03-26 | 2000-10-05 | Shionogi & Co., Ltd. | Derives d'acides amines $g(b) |
| AU3196300A (en) | 1999-03-26 | 2000-10-16 | Shionogi & Co., Ltd. | Carbocyclic sulfonamide derivatives |
| WO2000058304A1 (en) | 1999-03-26 | 2000-10-05 | Shionogi & Co., Ltd. | Heterocyclic sulfonamide derivatives |
| DE60023492T2 (de) | 1999-05-17 | 2006-07-20 | Novo Nordisk A/S | Glucagon antagonisten/inverse agonisten |
| UA71971C2 (en) | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
| JP2001247569A (ja) | 1999-08-12 | 2001-09-11 | Japan Tobacco Inc | ピロリジン誘導体又はピペリジン誘導体及びその医薬用途 |
| US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| US6458538B1 (en) | 1999-12-14 | 2002-10-01 | Ptc Therapeutics, Inc. | Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay |
| WO2001066534A2 (en) | 2000-03-09 | 2001-09-13 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
| US6498151B2 (en) | 2000-03-22 | 2002-12-24 | Merck Frosst Canada & Co. | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors |
| GB0011089D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | Gastrin and cholecystokinin receptor ligands (11) |
| OA12274A (en) | 2000-05-22 | 2006-05-09 | Aventis Pharma Inc | Arylmethylamine derivatives for use as tryptase inhibitors. |
| US7366402B2 (en) | 2000-06-02 | 2008-04-29 | Lg Electronics Inc. | Method and apparatus of recording a high definition digital television broadcast signal |
| JP2002105073A (ja) | 2000-09-27 | 2002-04-10 | Shionogi & Co Ltd | 新規マトリックスメタロプロテアーゼ阻害剤 |
| AUPR362001A0 (en) | 2001-03-08 | 2001-04-05 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| RU2003133750A (ru) | 2001-04-19 | 2005-05-10 | Байер АГ (DE) | Арилсульфонамиды в качестве антивирусных агентов |
| JP2005504014A (ja) | 2001-06-08 | 2005-02-10 | サイトビア インコーポレイテッド | カスパーゼの活性化因子およびアポトーシスの誘導因子としての置換された３−アリール−５−アリール−［１，２，４］−オキサジアゾール類および類似体、並びにその使用法 |
| GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| MY151199A (en) | 2001-11-02 | 2014-04-30 | Rigel Pharmaceuticals Inc | Substituted diphenyl heterocycles useful for treating hcv infection |
| AU2003247610A1 (en) | 2002-06-21 | 2004-01-06 | Ptc Therapeutics, Inc. | METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY |
| AU2003252136A1 (en) | 2002-07-24 | 2004-02-09 | Ptc Therapeutics, Inc. | METHODS FOR IDENTIFYING SMALL MOLEDULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY |
| AU2003256755A1 (en) | 2002-07-24 | 2004-02-09 | Ptc Therapeutics, Inc. | Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations |
| US7291603B2 (en) | 2002-07-24 | 2007-11-06 | Ptc Therapeutics, Inc. | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations |
| EP1525185A1 (en) | 2002-07-24 | 2005-04-27 | PTC Therapeutics, Inc. | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| TW200424183A (en) | 2002-08-09 | 2004-11-16 | Nps Pharma Inc | New compounds |
| US7074809B2 (en) | 2002-08-09 | 2006-07-11 | Astrazeneca Ab | Compounds |
| GB0303503D0 (en) | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
| US7555125B2 (en) | 2003-08-14 | 2009-06-30 | Broadcom Corporation | Systems and methods for generation of time-dependent control signals for video signals |
| HUE047569T2 (hu) | 2003-04-11 | 2020-04-28 | Ptc Therapeutics Inc | 1,2,4-oxadiazol-benzoesav vegyület és nonszensz szupresszióra történõ alkalmazása |
| WO2004110351A2 (en) | 2003-05-14 | 2004-12-23 | Anadys Pharmaceuticals, Inc. | Heterocyclic compounds for treating hepatitis c virus |
| JP3852934B2 (ja) | 2003-05-20 | 2006-12-06 | 株式会社バンダイナムコゲームス | 画像処理システム、プログラム及び情報記憶媒体 |
| US20050037052A1 (en) | 2003-08-13 | 2005-02-17 | Medtronic Vascular, Inc. | Stent coating with gradient porosity |
| KR100565056B1 (ko) | 2003-08-14 | 2006-03-30 | 삼성전자주식회사 | Ａｖ 데이터를 ｅｎａｖ 모드로 재생하는 방법, 그 장치및 그 정보저장매체 |
| WO2005060961A2 (en) | 2003-12-18 | 2005-07-07 | Astrazeneca Ab | Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd) |
| WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| US20080207538A1 (en) * | 2004-03-11 | 2008-08-28 | Lawrence David S | Enhanced Production of Functional Proteins From Defective Genes |
| DE102004013599A1 (de) * | 2004-03-19 | 2005-10-06 | Robert Bosch Gmbh | Ansteuerschaltung zum Ansteuern einer leistungselektronischen Schaltung sowie Verfahren hierzu |
| EP2402323A3 (en) | 2004-10-13 | 2012-05-30 | PTC Therapeutics, Inc. | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases |
| PT2402002T (pt) | 2005-04-08 | 2018-10-08 | Ptc Therapeutics Inc | Composições de 1,2,4-oxadiazole oralmente activo para terapia de supressão de mutações nonsense |
| MX2009002439A (es) | 2006-09-08 | 2009-03-27 | Ptc Therapeutics Inc | Procesos para la preparacion de acidos 1,2,4-oxadiazolbenzoicos. |
| US8101641B2 (en) | 2006-09-25 | 2012-01-24 | Ptc Therapeutics, Inc. | Hydroxylated 1,2,4-oxadiazole benzoic acid compounds and compositions thereof |
| PL2076501T3 (pl) | 2006-09-25 | 2016-06-30 | Ptc Therapeutics Inc | Postacie krystaliczne kwasu 3-[5-(2-fluorofenylo)[1,2,4]oksadiazol-3-ilo]-benzoesowego |
| RS54025B1 (sr) | 2006-10-12 | 2015-10-30 | Ptc Therapeutics Inc. | Postupci doziranja oralno aktivnog 1,2,4-oksadiazola za supresionu terapiju nonsens mutacije |
| WO2009151546A2 (en) | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
-
2007
- 2007-03-29 RU RU2008142957/15A patent/RU2462246C2/ru not_active IP Right Cessation
- 2007-03-29 WO PCT/US2007/008268 patent/WO2007117438A2/en not_active Ceased
- 2007-03-29 MX MX2008012515A patent/MX2008012515A/es active IP Right Grant
- 2007-03-29 IN IN4406CHN2014 patent/IN2014CN04406A/en unknown
- 2007-03-29 JP JP2009503082A patent/JP5367563B2/ja not_active Expired - Fee Related
- 2007-03-29 NZ NZ571899A patent/NZ571899A/en not_active IP Right Cessation
- 2007-03-29 AU AU2007235524A patent/AU2007235524B2/en not_active Ceased
- 2007-03-29 EP EP07754745A patent/EP2007365A2/en not_active Withdrawn
- 2007-03-29 CN CNA2007800201278A patent/CN101505739A/zh active Pending
- 2007-03-29 CA CA2647903A patent/CA2647903C/en not_active Expired - Fee Related
- 2007-03-29 BR BRPI0710213-5A patent/BRPI0710213A2/pt not_active IP Right Cessation
- 2007-03-29 NZ NZ596965A patent/NZ596965A/xx not_active IP Right Cessation
- 2007-03-29 EP EP11152243A patent/EP2387995A1/en not_active Withdrawn
- 2007-03-29 US US12/294,952 patent/US9289398B2/en not_active Expired - Fee Related
- 2007-03-29 SG SG201102327-2A patent/SG170819A1/en unknown
-
2008
- 2008-09-28 IL IL194454A patent/IL194454A/en not_active IP Right Cessation
- 2008-10-24 NO NO20084488A patent/NO20084488L/no not_active Application Discontinuation
-
2012
- 2012-10-18 IL IL222557A patent/IL222557A/en active IP Right Grant
-
2013
- 2013-06-25 JP JP2013133071A patent/JP5798154B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-16 US US15/044,225 patent/US20160199357A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SG170819A1 (en) | 2011-05-30 |
| WO2007117438A3 (en) | 2008-10-23 |
| RU2008142957A (ru) | 2010-05-10 |
| JP2013234189A (ja) | 2013-11-21 |
| AU2007235524B2 (en) | 2013-09-12 |
| WO2007117438A2 (en) | 2007-10-18 |
| NO20084488L (no) | 2008-12-19 |
| JP2009532368A (ja) | 2009-09-10 |
| IL194454A (en) | 2013-01-31 |
| IL222557A (en) | 2016-09-29 |
| RU2462246C2 (ru) | 2012-09-27 |
| EP2007365A2 (en) | 2008-12-31 |
| IL222557A0 (en) | 2012-12-31 |
| EP2387995A1 (en) | 2011-11-23 |
| CN101505739A (zh) | 2009-08-12 |
| MX2008012515A (es) | 2008-11-19 |
| AU2007235524A1 (en) | 2007-10-18 |
| CA2647903A1 (en) | 2007-10-18 |
| US20110046136A1 (en) | 2011-02-24 |
| US20160199357A1 (en) | 2016-07-14 |
| NZ596965A (en) | 2013-06-28 |
| JP5367563B2 (ja) | 2013-12-11 |
| JP5798154B2 (ja) | 2015-10-21 |
| NZ571899A (en) | 2012-07-27 |
| BRPI0710213A2 (pt) | 2011-04-12 |
| US9289398B2 (en) | 2016-03-22 |
| CA2647903C (en) | 2016-12-13 |
| IL194454A0 (en) | 2009-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN04406A (https=) | ||
| PE20160947A1 (es) | Composicion farmaceutica oral que comprende acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]benzoico | |
| ES2292614T3 (es) | Formulacion oral de fusion rapida de un inhibidor de ciclooxigenasa-2. | |
| US20120245186A1 (en) | Combination cancer therapy with hsp90 inhibitory compounds | |
| JP2017528494A (ja) | ｓＧＣ刺激剤 | |
| HRP20200753T1 (hr) | Farmaceutske formulacije koje sadrže dapagliflozin propilen glikol hidrat | |
| HRP20160450T1 (hr) | Novi inhibitori reduktaze s-nitrozoglutationa | |
| JP2003528918A5 (https=) | ||
| RU2014115427A (ru) | Фармацевтические композиции замещенных хиназолинонов | |
| WO2007048219A3 (en) | Sustained drug release composition | |
| IL231890A0 (en) | 7,3-diamino-10h-phenothiazine salts and their use | |
| JP2006520778A5 (https=) | ||
| WO2006098918A3 (en) | Substituted gamma lactams as therapeutic agents | |
| JP2007039461A5 (https=) | ||
| CA2687741A1 (en) | Stabilized amorphous forms of imatinib mesylate | |
| MY147310A (en) | A solid pharmaceutical composition containing 2-ethoxy-1-{ [2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylic acid or a salt thereof, a fat and oil-like substace having low melting point and a low viscosity binder | |
| JP2007091758A5 (https=) | ||
| JP2005530787A5 (https=) | ||
| KR20220087443A (ko) | 셀렉시파그를 포함하는 약제학적 조성물 | |
| ES2404811T3 (es) | Formulaciones farmacéuticas de olmesartán | |
| JP2004517151A5 (https=) | ||
| TNSN08447A1 (en) | Combination comprising an iron chelator and an anti-neoplastic agent and use thereof | |
| WO2008005352A3 (en) | Solid dose formulations of a thrombin receptor antagonist | |
| ES2437916T3 (es) | Composición de raloxifeno | |
| WO2006053089A3 (en) | Methods and formulations for making pharmaceutical compositions containing bupropion |